NutriBand Inc.
No SEC Form 4 filings for $NTRBW in the last 30 days.
See all $NTRBW insider activity →Nutriband (NTRB) raised $1.75M from warrant exercises, with proceeds funding AVERSA Fentanyl's clinical development and FDA application. The company estimates peak U.S. sales of $80M to $200M for the abuse-deterrent opioid patch.
Nutriband Inc. (NTRB) filed a new patent application for its AVERSA abuse-deterrent transdermal technology, aiming to enhance its protection and extend it to 2046. The patent covers improved formulations and methods to deter abuse. AVERSA is designed to reduce misuse risk for drugs like opioids and stimulants. NTRB's stock closed at $6.76, up 1.12%.
Nutriband Inc. (NASDAQ: NTRB) marked its fifth anniversary on Nasdaq, celebrating milestones like AVERSA™ Fentanyl's progress and $8.7M raised in 2021. The company reported revenue growth, patent expansions, and a 25% preferred stock dividend in 2025. CEO Gareth Sheridan outlined plans to advance AVERSA™ Fentanyl toward FDA approval and commercialization.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning NTRBW (NutriBand Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent NTRBW coverage spans financial news and corporate actions.
Nutriband (NTRB) raised $1.75M from warrant exercises, with proceeds funding AVERSA Fentanyl's clinical development and FDA application. The company estimates peak U.S. sales of $80M to $200M for the abuse-deterrent opioid patch.
Nutriband Inc. (NTRB) filed a new patent application for its AVERSA abuse-deterrent transdermal technology, aiming to enhance its protection and extend it to 2046. The patent covers improved formulations and methods to deter abuse. AVERSA is designed to reduce misuse risk for drugs like opioids and stimulants. NTRB's stock closed at $6.76, up 1.12%.
Nutriband Inc. (NASDAQ: NTRB) marked its fifth anniversary on Nasdaq, celebrating milestones like AVERSA™ Fentanyl's progress and $8.7M raised in 2021. The company reported revenue growth, patent expansions, and a 25% preferred stock dividend in 2025. CEO Gareth Sheridan outlined plans to advance AVERSA™ Fentanyl toward FDA approval and commercialization.
NutriBand Inc. (NTRB) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Financial Statements and Exhibits Nutriband Inc. (“Nutriband” or the “Company”) announced on September 21, 2026 that that its publicly traded warrants (Nasdaq: NTRBW) will expire in accordance with their original terms at 5:00 p.m. Eastern Time on September 30, 2026. Tr
NutriBand Inc. (NTRB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001676047 0001676047 2026-06-01 2026-06-01 0001676047 us-gaap:CommonStockMember 2026-06-01 2026-06-01 0001676047 NTRB:WarrantsMember 2026-06-01 2026-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CUR
AlphAI scores every news story that mentions NTRBW with an AI model for sentiment and relevance, and aggregates insider trades from NutriBand Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nutriband (NTRB) raised $1.75M from warrant exercises, with proceeds funding AVERSA Fentanyl's clinical development and FDA application. The company estimates peak U.S. sales of $80M to $200M for the abuse-deterrent opioid patch.
1 min readNutriband Inc. (NTRB) filed a new patent application for its AVERSA abuse-deterrent transdermal technology, aiming to enhance its protection and extend it to 2046. The patent covers improved formulations and methods to deter abuse. AVERSA is designed to reduce misuse risk for drugs like opioids and stimulants. NTRB's stock closed at $6.76, up 1.12%.
1 min readNutriband Inc. (NASDAQ: NTRB) marked its fifth anniversary on Nasdaq, celebrating milestones like AVERSA™ Fentanyl's progress and $8.7M raised in 2021. The company reported revenue growth, patent expansions, and a 25% preferred stock dividend in 2025. CEO Gareth Sheridan outlined plans to advance AVERSA™ Fentanyl toward FDA approval and commercialization.
2 min readNutriBand Inc. (NTRB) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Financial Statements and Exhibits Nutriband Inc. (“Nutriband” or the “Company”) announced on September 21, 2026 that that its publicly traded warrants (Nasdaq: NTRBW) will expire in accordance with their original terms at 5:00 p.m. Eastern Time on September 30, 2026. Tr
1 min readNutriBand Inc. (NTRB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001676047 0001676047 2026-06-01 2026-06-01 0001676047 us-gaap:CommonStockMember 2026-06-01 2026-06-01 0001676047 NTRB:WarrantsMember 2026-06-01 2026-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CUR
4 min readPositive FDA meeting ...
3 min readORLANDO, Fla., Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Nutriband Inc. ( NASDAQ:NTRB ) ( NASDAQ:NTRBW ) , a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received final meeting minutes from its recent virtual face-to-face meeting ...
3 min readORLANDO, Fla., Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Nutriband Inc. ( NASDAQ:NTRB ) ( NASDAQ:NTRBW ) , a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received final meeting minutes from its recent virtual face-to-face meeting ...
3 min readPositive FDA meeting ...
2 min readBrand Institute Partnership ...
2 min read